Clinical study on effect of thromboxane A2 synthetase inhibitor (OKY-046) to clarify the regulation of cerebral blood flow in cerebral thrombosis.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000179:Acrylates / Q000627:therapeutic use*; D000368:Aged; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008689:Methacrylates / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D013929:Thromboxane B2 / Q000097:blood; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D000179:Acrylates; D008689:Methacrylates; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D013930:Thromboxane-A Synthase; C034364:ozagrel